Lyrica Dose Response Study With Restless Legs Syndrome (RLS) Patients

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the effectiveness and tolerability of Lyrica at various dose levels in RLS patients

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Moderate to severe idiopathic RLS

• symptoms occur predominantly in the evening

• symptoms interfere with sleep onset or maintenance

Exclusion Criteria:

• Any secondary RLS

• require treatment for daytime RLS symptoms

• symptomatic neuropathies